, Tracking Stock Market Picks
Enter Symbol:
Cardiovascular Systems Inc. (CSII) [hlAlert]

up 171.60 %

Cardiovascular Systems Inc. (CSII) rated Buy with price target $32 by Dougherty & Company

Posted on: Thursday,  Oct 8, 2015  1:25 PM ET by Dougherty & Company

Dougherty & Company rated Buy Cardiovascular Systems Inc. (NASDAQ: CSII) on 10/08/2015. Previously Dougherty & Company rated Buy Cardiovascular Systems Inc.
(NASDAQ: CSII) on 04/11/2012., when the stock price was $8.84. Since then, Cardiovascular Systems Inc. has gained 171.61% as of 01/22/2016's recent price of $24.01.
If you would have followed the previous Dougherty & Company 's recommendation on CSII, you would have gained 171.6% of your investment in 1381 days.

Cardiovascular Systems, Inc.(CSI) is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. The Company?s primary product, the Diamondback 360 PAD System, is a catheter-based platform capable of treating a range of plaque types in leg arteries both above and below the knee. In August 2007, the United States Food and Drug Administration (FDA) granted the Company 510(k) clearance for use of the Diamondback 360 as a therapy for treatment of patients with peripheral artery disease (PAD). As of June 30, 2009, it was selling the Diamondback 360 in 556 accounts that had completed an estimated 15,000 procedures. On February 25, 2009, Replidyne, Inc. completed its merger with Cardiovascular Systems, Inc. Pursuant to the merger, Replidyne merged with and into Cardiovascular Systems, Inc., with Cardiovascular Systems, Inc. continuing after the merger as the surviving company and a wholly owned subsidiary of Replidyne.

Team The research group is composed of five senior analysts and two associate analysts. The senior analysts collectively have 44 years of securities industry experience, and include 3 MBA's, 2 CPA's, 2 PE's (professional engineer), a CFA and a CMA. The team has come together out of a passion for overlooked or misunderstood investment opportunities – generally in smaller-cap companies – and a love of in-depth research, with special emphasis on independent information sources and innovative thinking. Coverage Our research coverage is idea driven and balances the twin demands of opportunism for flexibility and universe consistency for maximization of information sources. Current sub-sectors of interest include: * Specialty retail * Internet security * Internet media * Auto-identification and data capture (AIDC & RFID) * Mobile computing * Specialty manufacturing * Chronic care management * Outpatient services * Medical devices * Healthcare IT
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/8/2015 1:25 PM Buy
13.40 32.00
as of 8/27/2015
1 Week   
1 Month down  -18.69 %
3 Months down  -18.96 %
1 YTD down  -29.97 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/23/2013 11:25 AM Buy
27.20 50.00
7/22/2013 11:25 AM Buy
21.40 28.00
3/11/2013 11:25 AM Buy
18.45 21.00
1/15/2013 1:25 PM Buy
14.69 17.50
4/11/2012 1:25 PM Buy
8.84 14.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy